Optimizing MSP reaction conditions of MGMT promoter in glioblastoma FFPE samples

Nikola M. Jovanović, Vesna Nikolov, Nataša Vidović, Jelena Vitorović, Svetlana Tošić, Vladimir Jovica Cvetković, Tatjana Mitrović, Tatjana Jevtović-Stoimenov

Abstract


The methylation status of the MGMT promoter represents the valuable prognostic and predictive marker in glioblastoma patients undergoing treatment with alkylating agents such as Temozolomide (TMZ). Although Formalin-Fixed and Paraffin-Embedded Tissue (FFPE) signifies the most commonly used source for tissue-based molecular testing, its use in Methylation-Specific Polymerase Chain Reaction analysis manifests certain limitations due to low DNA integrity. Our study aimed to identify the optimal MGMT promoter MSP reaction conditions concerning the utilization of bisulfite-converted FFPE-derived template DNA. Several optimizing reactions were conducted and subjected to ImageJ software analysis. As a result, 4U amount of HotStartTaq and 125 ng of template DNA were specified as necessary for successful MSP reactions. The confirmation of optimization success was obtained through comparison of semi-quantitative values of DNA methylation levels between reference Fresh Frozen tissue (FF) and corresponding FFPE sample obtained from the same GBM patient.

Keywords


glioblastoma, FFPE, methylation, MGMT, MSP, optimization, Taq polymerase

Full Text:

PDF

References


Chen, R., Smith-Cohn, M., Cohen, A.L., Colman, H. 2017: Glioma Subclassifications and Their Clinical Significance. Neurotherapeutics, 14:284-297 https://doi.org/10.1007/s13311-017-0519-x

Christians, A., Hartmann, C., Benner, A., Meyer, J., von Deimling, A., Weller, M., Wick, W., Weiler, M. 2012: Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. PLoS One, 7(3):e33449 https://doi.org/10.1371/journal.pone.0033449

de Ruijter, T.C., de Hoon, J.P., Slaats, J., de Vries, B., Janssen, M.J., van Wezel, T., Aarts, M.J., van Engeland, M., Tjan-Heijnen, V.C., Van Neste, L., Veeck, J. 2015: Formalin-fixed, paraffin-embedded (FFPE) tissueepigenomics using Infinium HumanMethylation450BeadChip assays. Models and Techniques, 95:833-842(2015) https://doi.org/10.1038/labinvest.2015.53

Dietrich, D., Uhl, B., Sailer, V., Holmes, E.E., Jung, M., Meller, S., Kristiansen, G. 2013: Improved PCR Performance Using Template DNA from Formalin-Fixed and Paraffin-Embedded Tissues by Overcoming PCR Inhibition. PLoS One, 8(10):e77771. https://doi.org/10.1371/journal.pone.0077771

Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S.N., Hidalgo, O.F., Vanaclocha, V., Baylin, S.B., Herman, J.G. 2000: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. The New England journal of medicine, 343(19):1350-4 https://doi.org/10.1056/NEJM200011093431901

Frommer, M., McDonald, L.E., Millar, D.S., Collis, C.M., Watt, F., Grigg, G.W., Molloy, P.L., Paul, C.L., 1992: A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proceedings of the National Academy of Sciences of the United States of America, 89(5):1827-1831 https://doi.org/10.1073/pnas.89.5.1827

Holmes, E.E., Jung, M., Meller, S., Leisse, A., Sailer, V., Zech, J., Mengdehl, M., Garbe, L.A., Uhl, B., Kristiansen, G., Dietrich, D. 2014: Performance Evaluation of Kits for Bisulfite-Conversion of DNA from Tissues, Cell Lines, FFPE Tissues, Aspirates, Lavages, Effusions, Plasma, Serum, and Urine. PLoS One, 9(4):e93933 https://10.1371/journal.pone.0093933

Kint, S., De Spiegelaere, W., De Kesel, J., Vandekerckhove, L., Van Criekinge, W. 2018: Evaluation of bisulfite kits for DNA methylation profiling in terms of DNA fragmentation and DNA recovery using digital PCR. PLoS One, 13(6): e0199091 https://doi.org/10.1371/journal.pone.0199091

Louis, D.N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W.K., Ohgaki, H., Wiestler, O.D., Kleihues, P., Ellison, D.W. 2016: The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica, 131(6):803-20 https://doi.org/10.1007/s00401-016-1545-1

Ludgate, J.L., Wright, J., Stockwell, P.A., Morison, I.M., Eccles, M.R., Chatterjee, A. 2017: A streamlined method for analysing genome-wide DNA methylation patterns from low amounts of FFPE DNA. BMC medical genomics, 10(1):54 https://doi.org/10.1186/s12920-017-0290-1

Patterson, K., Molloy, L., Qu, W., Clark, S. 2011: DNA Methylation: Bisulphite Modification and Analysis. Journal of Visualized Experiments, (56):3170 https://doi.org/10.3791/3170

Sengüven, B., Baris, E., Oygur, T., Berktas, M. 2014: Comparison of methods for the extraction of DNA from formalin-fixed, paraffin-embedded archival tissues. International journal of medical sciences, 11(5):494-9 https://doi.org/10.7150/ijms.8842

Soomro, S.H., Ting, L.R., Qing, Y.Y., Ren, M. 2017: Molecular biology of glioblastoma: Classification and mutational locations . The Journal of the Pakistan Medical Association, 67(9):1410-1414

Thon, N., Eigenbrod, S., Grasbon-Frodl, E.M., Lutz, J., Kreth, S., Popperl, G., Belka, C., Kretzschmar, H.A., Tonn, J.C., Kreth, F,W. 2011: Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide. Journal of neurology, neurosurgery, and psychiatry, 82(4):441–446 https://doi.org/10.1136/jnnp.2010.214593

Thon, N., Kreth, S., Kreth, F.W. 2013: Personalized treatment strategies in glioblastoma: MGMT promoter methylation status. Onco Targets and therapy, 6:1363-72. https://doi.org/10.2147/OTT.S50208

Tournier, B., Chapusot, C., Courcet, E., Martin, L., Lepage, C., Faivre, J., Piard, F. 2012: Why do results conflict regarding the prognostic value of the methylation status in colon cancers? The role of the preservation method. BMC Cancer, 12:12 https://doi.org/10.1186/1471-2407-12-12

Verhaak, R.G., Hoadley, K.A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M.D., Miller, C.D., Ding, L., Golub, T., Mesirov, J.P., Alexe, G., Lawrence, M, O’Kelly, M.,Temayo, P., Weir, B.A., Gabriel, S., Winckler, W., Gupta, S., Jakkula, L., Feiler, H.S., Hodgson, J.G., James, C.D., Sarkaria, J.N., Brennan, C., Kahn, A., Spellman, P.T., Wilson, R.K., Speed, T.P., Gray, J.W., Meyerson, M., Getz, G., Perou, C.M., Hayes, DN.; Cancer Genome Atlas Research Network. 2010: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 17(1):98-110 https://doi.org/10.1016/j.ccr.2009.12.020


Refbacks

  • There are currently no refbacks.